

16th September, 2024

To,  
Dy. General Manager  
Department of Corporate Services,  
BSE Ltd.,  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001

To,  
The Manager – Listing,  
National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 543322

Ref: Scrip Name: GLS

Dear Sir/Madam,

**Sub: Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 – Intimation of Investors/Analyst Meeting**

With reference to the captioned subject and pursuant to Regulation 30 and Para A of Part A of Schedule III of SEBI (Listing obligation and Disclosure Requirements) Regulations, 2015, please find below details of the meetings with Investor/Analyst which will be attended by the representatives of the Company:

Date	Name	Mode	Place
19th September, 2024	Kotak Healthcare Forum 2024	In person	Mumbai
23rd September, 2024	DAM Capital Pharmaceuticals Conference	In person	Mumbai

The schedule and mode of meeting may undergo a change due to exigencies on part of the Investor/Analyst/Company.

You are requested to kindly take a note of the same.

Thanking You,

Your Sincerely,

**For Glenmark Life Sciences Limited**

**Rudalf Corriea**  
**Company Secretary and Compliance Officer**

Glenmark Life Sciences Limited

Corporate Office: 4th Floor, OIA House, 470, Cardinal Gracious Road, Andheri (E), Mumbai 400 099, India.

Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpath, Solapur - 413 213, India.

T: 91 22 68297979 CIN: L74900PN2011PLC139963 E: complianceofficer@glenmarklifesciences.com W: www.glenmarklifesciences.com